Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its Category 1 drug cofrogliptin (HSK7653), a long-acting dipeptidyl peptidase-4 (DPP-4) inhibitor. The drug is now approved for use in improving blood sugar control in patients with type 2 diabetes (T2D).
Cofrogliptin is designed to enhance the plasma concentration of endogenous glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), thereby improving glycemic control. Prior clinical studies have demonstrated that cofrogliptin effectively reduces blood sugar levels without causing gastrointestinal adverse reactions or weight gain. The drug also does not increase the risk of hypoglycemia or cardiovascular events. Additionally, it does not require dosage adjustment for patients with mild to moderate liver and kidney function impairment.- Flcube.com
